Palbociclib overcomes afatinib resistance in non-small cell lung cancer
As a Second generation tyrosine kinase inhibitor (TKI), afatinib is approved to treat advanved/metastatic EGFR-mutant NSCLC (non-small cell lung cancer). However, the clinical application of afatinib is limited via acquired resistance. It has been revealed that CDK4/6 inhibitors hinder proliferation...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-01-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332218367520 |